版本:
中国

BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint

Oct 13 Oncogenex Pharmaceuticals Inc :

* Oncogenex announces results from the phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer

* Oncogenex Pharmaceuticals Inc - trial did not meet primary endpoint

* Oncogenex Pharmaceuticals -continuing to work with mts health partners who has been advising co in exploration of strategic alternatives since mid-August Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐